Related Blog Posts from the Wikinvest Wire

Amgen (AMGN)   Subscribe to Amgen (AMGN) content from the Wikinvest Wire
 » Back to Amgen (NASDAQ:AMGN) Stock Page

  

12/17/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces 30 Percent Increase In 2015 First Quart... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Dec. 17, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that its Board of Directors declared a $0.79 per share dividend for the first quarter of 2015. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative [...]

12/11/14Company Update (NASDAQ:AMGN): Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ ... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and LONDON, Dec. 11, 2014 /PRNewswire/ -- Amgen (AMGN) and AstraZeneca (AZN) today announced that additional results from AMAGINE-1TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in patients with moderate-to-severe plaque psoriasis will be presented at the Psoriasis: From Gene to Clinic International Congress [...]

12/3/14Company Update: Amgen Inc (NASDAQ:AMGN) – Actress Adamari López And Amgen Launch Spanish-Langu... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Dec. 3, 2014 /PRNewswire/ -- Amgen (AMGN) today launched Quimioterapia: Mitos y Realidades, a Spanish-language extension of the Chemotherapy: Myths or FactsTM awareness initiative for cancer patients and their caregivers, featuring actress and Emmy® award-winning television personality Adamari López. In 2005, López was diagnosed with and treated for [...]

11/24/14Stock Update (NASDAQ:AMGN): Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies O... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 24, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 and RILOMET-2 studies. Amgen's decision is based on a planned safety review by the RILOMET-1 independent data monitoring committee that found [...]

11/18/14Company Update (NASDAQ:AMGN): Amgen Presents Long-Term Data Showing Efficacy And Safety Of Invest... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 18, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density ... Read more on this. Amgen Inc. (AMGN), valued at $123.41B, opened at $158.83.   Today’s price [...]

11/14/14Company Update (NASDAQ:AMGN): Amgen To Present At The Jefferies Global Healthcare Conference (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 14, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will participate at the Jefferies Global Healthcare Conference on Wednesday, Nov. 19, 2014, in London, beginning at 8:40 a.m. GMT. ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $119.94B, started trading this morning [...]

11/12/14Stock Update (NASDAQ:AMGN): The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educati... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 12, 2014 /PRNewswire/ -- The Amgen Foundation today announced that the Amgen Scholars Program is expanding its presence with new host institutions in the U.S., Europe, and, ... Read more on this. Amgen Inc. (AMGN), with a current value of $123.02B, finished at $162.42.   [...]

11/10/14Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA Accepts Amgen’s Biologics License Application For... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application ... Read more on this. Amgen Inc. (AMGN), valued at $123.63B, opened at $161.01.   Looking at the [...]

11/6/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Highlights New Data In The Treatment Of Blood C... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 /PRNewswire/ -- Amgen (AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company's oncology and hematology portfolios have been accepted for presentation at the 56th Annual Meeting and Exposition of the American Society [...]

11/4/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall surv... (Jutia Group)

[Reuters] - Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Statistically significant improvement in overall survival was the secondary goal of the trial. The trial, TRINOVA-1, is the first of three late-stage studies to evaluate safety and effectiveness of the [...]

10/29/14iShares NASDAQ Biotechnology Index Tops: Amgen, Gilead Exhaustion (The Market Financial)

Just a couple months ago, Janet Yellen issued a warning that biotechnology may be in a bubble. Today, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) are 20% higher. While Janet Yellen was wrong at the time, we should all remember that Alan Greenspan issued the same warning on Dot.com companies in the late 1990's. He [...]

10/28/14Market Update (NASDAQ:AMGN): Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans (Jutia Group)

[PR Newswire] - NEW YORK, Oct. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined the Company's strategy, growth objectives and capital allocation plans, and provided financial guidance for 2015. Robert A. Bradway, ... Read more on this. Amgen Inc. (AMGN), valued at $118.95B, began trading this morning at $151.75.   [...]

10/23/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Webcast 2014 Business Review Meeting On Octobe... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Oct. 23, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will hold its Business Review Meeting on Tuesday, Oct. 28, 2014, at the Conrad New York, 102 North End Avenue, New York City, beginning at 8 a.m. ET. In the meeting, Robert A. Bradway, chairman and chief [...]

10/21/14Company Update (NASDAQ:AMGN): Amgen Statement Regarding Third Point Investment (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Oct. 21, 2014 /PRNewswire/ -- Amgen (AMGN) issued the following statement with respect to media inquiries concerning Third Point LLC's equity position in Amgen: Amgen maintains an active, engaged dialogue with all shareholders. Amgen has always appreciated the perspectives of all of its shareholders, including Third Point, and [...]

10/17/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Appointment Of R. Sanders Williams To B... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the appointment of R. Sanders Williams, M.D., president of Gladstone Institutes and Gladstone's Robert W. and Linda L. Mahley Distinguished Professor. "We are pleased to welcome Dr. Sandy Williams to the Amgen Board," said Robert A. Bradway, chairman and [...]

9/22/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Submits Biologics License Application for Inves... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 22, 2014 /PRNewswire/ -- Amgen (AMGN) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for its investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) [...]

9/15/14Company Update (NASDAQ:AMGN): Amgen Announces Results From Several New Exploratory Analyses Evalu... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 15, 2014 /PRNewswire/ -- Amgen (AMGN) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, which found that treatment with Prolia® (denosumab) for eight years enabled a substantial proportion of women with osteoporosis to achieve non-osteoporotic [...]

9/10/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces 23 Abstracts To Be Presented At The Ame... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 10, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will present data from multiple Prolia® (denosumab) and romosozumab study analyses at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting being held in Houston, Sept. 12-15, 2014. The data that will be presented [...]

9/2/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Submits Marketing Authorization Application For T... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 2, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Talimogene laherparepvec is [...]

8/28/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen submits U.S. application to sell cholesterol-fi... (Jutia Group)

[Reuters] - Amgen Inc said it submitted an application to the U.S. Food and Drug Administration to market its cholesterol-lowering drug, evolocumab. The injectable drug works by blocking PCSK9, a naturally occurring ... Read more on this. Amgen Inc. (AMGN), valued at $105.54B, started the session at $137.65.   Looking [...]

8/27/14Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA Grants Amgen Priority Review Designation For Ivabra... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node, the [...]

8/21/14Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly psoriasis drug impresses; battle nears with Amge... (Jutia Group)

[Reuters] - An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG. Based on favorable results from Phase III trials, Lilly said Thursday it would seek marketing approval in [...]

8/21/14Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly psoriasis drug impresses; battle nears wit... (Jutia Group)

[Reuters] - An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG. Based on favorable results from Phase III trials, Lilly said Thursday it would seek marketing approval in [...]

8/18/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Second... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Aug. 18, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. Read more on this. Amgen [...]

8/13/14Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Issues Voluntary Recall of Aranesp® (darbepoeti... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp® (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed [...]

8/4/14Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In ... (Jutia Group)

[at noodls] - THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 4, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated ... Read more on this. Amgen Inc. (AMGN), currently valued at $96.23B, began trading this morning at $129.21.   [...]

7/31/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Second Quarter 2014 Revenues Increased 11 P... (Jutia Group)

[at noodls] - Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 Second Quarter 2014 GAAP EPS Were $2.01 2014 Total Revenues ... Read more on this. Amgen Inc. (AMGN), valued at $96.69B, opened at $128.28.   [...]

7/29/14Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Second Quarter 2014 Revenues Increased 11 Pe... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., July 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2014. Key results include: Total revenues increased 11 percent to $5,180 ... Read more on this. Amgen Inc. (AMGN), valued at $93.35B, opened at $122.52.   Today’s [...]

7/25/14Amgen Inc (NASDAQ:AMGN) – Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVA... (Jutia Group)

[at noodls] - Whippany, NJ and South San Francisco, CA . - Jul 25, 2014 Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ:AMGN), today announced that an investigational Phase 3 trial of NEXAVAR® ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $92.34B, began trading this [...]

7/24/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 Second Quarter Financia... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., July 24, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and [...]

6/18/14AMGN Named A Top Socially Responsible Dividend Stock (Jutia Group)

Amgen Inc has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like [...]

5/27/14Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen and Onyx Data at ASCO 2014 Highlight Oncology Pi... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 27, 2014 /PRNewswire/ -- Amgen (AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced data from several studies of both pipeline and marketed products will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held [...]

5/12/14Amgen Inc (NASDAQ:AMGN) – Amgen Names Steven K. Galson, Senior Vice President, Global Regulator... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., May 12, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the appointment of Steven K. Galson, M.D., M.P.H., to the position of senior vice president, Global Regulatory Affairs and Safety, effective May 19. Galson will report to Sean E. Harper, M.D., executive vice president, Research and Development, and will [...]

5/9/14Amgen Inc (NASDAQ:AMGN) – Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and LONDON, May 9, 2014 /PRNewswire/ -- Amgen (AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. A significantly higher proportion of patients treated with brodalumab achieved a [...]

4/22/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s First Quarter 2014 Revenues Increased 7 Perce... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2014. Key results include: Total revenues increased 7 percent to $4,521 ... Read more on this. Amgen Inc. (AMGN), valued at $90.07B, opened this morning at $117.24.   [...]

4/17/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 First Quarter Financial... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., April 17, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and [...]

4/4/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Provides Update On Phase 3 Study Of Talimogene La... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ -- Amgen (AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment [...]

3/26/14Amgen Inc (NASDAQ:AMGN) – Amgen To Webcast Investor Meeting At Upcoming American College of Car... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 26, 2014 /PRNewswire/ -- Amgen (AMGN) will host a webcast investor meeting at the American College of Cardiology's 63rd Annual Scientific Session (ACC.14) in Washington, D.C. on Sunday, March 30, at 7 p.m. EDT. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, [...]

3/24/14Company Update (NASDAQ:AMGN): Phase 3 Pivotal Data On Amgen’s Novel Investigational Cholesterol... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 24, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or [...]

3/17/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase ... (Jutia Group)

[at noodls] - THOUSAND OAKS, Calif., March 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating ... Read more on this. Amgen Inc. (AMGN), valued at $93.62B, started the session at $123.09.   Looking [...]

3/14/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Talimogene Laherparepvec Reduced Size Of Mela... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 14, 2014 /PRNewswire/ -- Amgen (AMGN) today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts of the body. The analysis recorded tumor-level responses [...]

3/5/14Amgen Inc (NASDAQ:AMGN) | Amgen Announces 2014 Second Quarter Dividend (Jutia Group)

[at noodls] - THOUSAND OAKS, Calif., March 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the second quarter of 2014. The dividend will ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $95.27B, started the session [...]

2/21/14Amgen Inc (NASDAQ:AMGN) – Amgen To Present At The RBC Capital Markets’ Global Healthcare Conf... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Feb. 21, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the RBC Capital Markets' Global Healthcare Conference at 4:05 p.m. ET on Wednesday, Feb. 26, 2014, at the New York ... Read more on this. Amgen Inc. (AMGN), with a current value of $93.51B, opened this [...]

1/31/14Amgen Inc (NASDAQ:AMGN) – 2014′s Better Biotech Buy: Biogen Idec, Inc. vs. Amgen, Inc. (Jutia Group)

[at Motley Fool] - Big biotech has surged in the past few years, with Biogen and Amgen among the two leaders in this industry. Which stock looks the best for investors in 2014? Read more on this. Amgen Inc. (AMGN), valued at $90.34B, started trading this morning at $118.55.   [...]

1/30/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase 3 ... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 30, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 RUTHERFORD-2 ( R ed U ction of LDL-C with PCSK9 Inhibi T ion in HE te R ozygous F amilial Hyperch ... Read more on this. Amgen Inc. (AMGN), valued at $91.17B, opened at [...]

1/28/14Amgen Inc (NASDAQ:AMGN) – Amgen’s 2013 Revenues Increased 8 Percent To $18.7 Billion And Adju... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2013. Key results include: For the fourth quarter, total ... Read more on this. Amgen Inc. (AMGN), valued at $91.07B, opened this morning at $118.39.   [...]

1/27/14Company Update: Amgen Inc (NASDAQ:AMGN) – Whisper Number: How Will Amgen’s Stock Move After E... (Jutia Group)

[at Wall St. Cheat Sheet] - Amgen has a 62 percent positive surprise history, having topped the whisper in 32 of the 52 earnings reports for which we have data. Read more on this. Amgen Inc. (AMGN), valued at $89.38B, started trading this morning at $119.50.   During today's session, [...]

1/24/14Amgen Inc (NASDAQ:AMGN) | Amgen: The Best Value In Biotech (Jutia Group)

[at Seeking Alpha] - The biotech industry offers investors an outsize chance to make an above average return on capital in a short period of time. The industries life blood revolves around developing cutting edge remedies ... Read more on this. Amgen Inc. (AMGN), valued at $90.22B, opened this morning at $122.59. [...]

1/23/14Amgen Inc (NASDAQ:AMGN) – What You Need to Know About Amgen’s Oncology Line-Up (Jutia Group)

[at Motley Fool] - Until recently, Amgen’s oncology presence has been somewhat limited. Over the next several years we can expect the California juggernaut to create big waves with these cancer fighting therapies. Read more on this. Amgen Inc. (AMGN), valued at $93.15B, ended session yesterday at $124.37.   Looking [...]

1/16/14Amgen, Inc. (NASDAQ:AMGN) | Will Conservative Guidance Sink This Big Biotech in 2014? (Jutia Group)

[at Motley Fool] - Celgene recently slipped on weaker-than-expected guidance for 2014. Should investors buy the dip? Let’s compare Celgene to its big biotech peers Amgen, Biogen, and Gilead Sciences, to better understand ... Read more on this. Amgen Inc. (AMGN), currently valued at $89.70B, began trading this morning at $118.82.   [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki